MYC and neuroblastoma: Multiple preclinical data support DFMO-based therapies may achieve anticancer efficacy with deregulated MYC signaling, such as refractory and high-risk neuroblastomas.118 Theoretically, DFMO, alone or in combination with other agents, could be effective in MYC-driven cancers.